Recombinant human FLT3 (R595_E596insEY) (571-993) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Catalog No. F12-12GG
Catalog No. | Pack Size | Price (USD) | |
---|---|---|---|
F12-12GG-05 | 5 ug | $226 | |
F12-12GG-10 | 10 ug | $325 | |
F12-12GG-BULK | BULK | Contact Us |
Overview:
Fms-related tyrosine kinase 3 (FLT3) is a gene that encodes for a tyrosine kinase that activates pathways in hematopoietic cells important in cellular proliferation. FLT3 is frequently mutated in acute myeloid leukemia (AML), myelodysplastic syndromes, other hematologic malignancies, and colorectal cancer. FLT3 mutations are observed in 24.3% of AML, of which internal tandem duplications (ITD) are the most frequent. FLT3 ITD occurs when sequences of less than ten to several hundred bases in length are repeated within the juxtamembrane domain are always “in-frame”.
Gene Aliases:
FLT3 (R595_E596insEY), FLK2, STK1, CD135
Genbank Number:
References:
1. http://www.mycancergenome.org/content/disease/acute-myeloid-leukemia/flt3/277/
2. Fathi AT, et al: Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res. 1(2):175-89, 2011
Specific Activity:
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Purity:
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability, and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Molecular Weight:
73 kDa
Krejci Pavel et al., NF449 Is a Novel Inhibitor of Fibroblast Growth Factor Receptor 3 (FGFR3) Signaling Active in Chondrocytes and Multiple Myeloma Cells Journal of Biological Chemistry July 2010 10.1074/jbc.M109.083626
JW Singer et al., Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. Journal of Experimental Pharmacology August 2016 10.2147/JEP.S110702
AKT/PKB Pathway, Angiogenesis, Cancer, ERK/MAPK Pathway, Receptor Tyrosine Kinases
STAY CONNECTED
Fax: 1-604-232-4601